Our Revolutionary Science

Discover our innovative treatments that are revolutionizing the field of metabolic disease therapeutics.

The Problem

Addressing the Epidemic of Metabolic Disease

By 2035, it is estimated that 1 in 2 adults will be living with obesity, a risk factor contributing to metabolic diseases such as diabetes, fatty liver and cardiovascular disease. The economic impact of this epidemic is projected to total $4.3 trillion worldwide (3% of global GDP) if left unaddressed.


Population of Adults Overweight or Obese Globally


Increased Risk of Type 2 Diabetes


Worldwide Patients With Metabolic Syndrome

Enter The ReRx Solution

ReRx’s research program utilizes complementary targeting of metabolic pathways to improve clinical outcomes compared to pharmacologically similar clinical candidates.

Addressing unmet needs

Creating therapies to help patients address specific and multiple facets of metabolic diseases over the long term

Targeting energy expenditure

Modulating metabolism to increase energetic output in negative energy balance as opposed to caloric intake

Improving clinical outcomes

Novel mechanism of action overcomes shortcomings of current treatment options

Experienced team

Dedicated team of scientists and industry leaders with decades of research and drug development experience

Lead Candidate: ReRx-001

Our groundbreaking therapeutics revolutionize the treatment of metabolic diseases

Metabolic modulator targeting pathways involved in energy expenditure and homeostasis that improve outcomes of single-targeting therapeutics

Marked whole body weight reduction (fat mass loss with minimal changes in lean mass)

Well-tolerated, orally bioavailable, and efficacious in murine dietary models of metabolic disease (20+ completed preclinical studies)

Lack of adverse side effects compared to similar pharmacological class

Potential synergistic effect on weight loss in combination with incretin analogs (semaglutide, tirzepatide)

Combination Uses: ReRx-001

Combination development with Incretin-based therapies

Distinct pharmacological and target profile from incretin-based therapeutics (semaglutide, tirzepatide)

Potential synergistic effect on weight loss in combination with incretin analogs, specifically in fat mass

Combination treatment outperfomed single-agent treatments in multiple metabolic parameters (blood lipids, insulin sensitivity)

Discover Innovative Therapeutics

Get in touch with us to see our research and get to know more